Zobrazeno 1 - 10
of 1 392
pro vyhledávání: '"Sodium–glucose cotransporter 2 inhibitor"'
Autor:
Dong Hee Kim, Min Jin Lee, Dasol Kang, Ji Young Lee, Sujin Park, Ah Reum Khang, Ji Hyun Bae, Joo Yeon Kim, Su Hyun Kim, Yang Ho Kang, Dongwon Yi
Publikováno v:
Current Issues in Molecular Biology, Vol 46, Iss 11, Pp 12417-12427 (2024)
Sodium-glucose cotransporter-2 (SGLT2) inhibitors regulate blood glucose levels in patients with type 2 diabetes mellitus and may also exert anti-inflammatory and anti-atherosclerotic effects by promoting M2 macrophage polarization. Although SGLT2 is
Externí odkaz:
https://doaj.org/article/1250a9a9bc3047f1bec604dd32dc3f26
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-11 (2024)
Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have a reliable hypoglycaemic and weight-loss effect that can intervene in obesity, which is the basis of type 2 diabetes pathology. GLP-1RA therapy has shown potential benefits in reducin
Externí odkaz:
https://doaj.org/article/35107f0646fc46afa0af76b5cc1e3b4a
Autor:
Ryoichi Ishibashi, Masaya Koshizaka, Yoko Takatsuna, Tomoaki Tatsumi, Yoshiro Maezawa, Yuki Shiko, Yosuke Inaba, Yohei Kawasaki, Yusuke Kashiwagi, Eiryo Kawakami, Shuichi Yamamoto, Koutaro Yokote
Publikováno v:
Journal of Diabetes Investigation, Vol 15, Iss 9, Pp 1231-1238 (2024)
Abstract Aims/Introduction Severe diabetic macular edema (DME) is often resistant to anti‐vascular endothelial growth factor therapy. Steroids are particularly effective at reducing edema by suppressing inflammation; they are also used as an altern
Externí odkaz:
https://doaj.org/article/b4f69585b8044506bf8a7df97b4fd7f3
Autor:
Pankaj Jariwala, Gururaj Pramod Kulkarni, Arshad Punjani, Kishan Hari, Dilip Babu Madhawar, Babu Dilip, Dilip Gude
Publikováno v:
Journal of the Practice of Cardiovascular Sciences, Vol 10, Iss 2, Pp 71-76 (2024)
Background: Dapagliflozin and sodium–glucose cotransporter 2 inhibitors reduce the risk of cardiac death and hospitalization for heart failure (HF), regardless of the patient’s status with type 2 diabetes mellitus (T2D). Further investigation is
Externí odkaz:
https://doaj.org/article/5f7a44274c254e69bacf9a1ebf72a905
Autor:
Tomohiro Hayashida, Yosuke Kuroko, Shuji Shimizu, Tsuyoshi Akiyama, Takanori Suezawa, Yukio Kioka, Yasuhiro Kotani, Toshiaki Shishido, Shingo Kasahara
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract It has been suggested that sodium-glucose cotransporter 2 (SGLT2) inhibitors have cardioprotective effects during myocardial ischemia/reperfusion (I/R) independent of glucose-lowering action. However, the effects of SGLT2 inhibitors on struc
Externí odkaz:
https://doaj.org/article/6b809e4bd8cb4acc9481d6544a8853b0
Autor:
Tasuku Imada, Naoto Katakami, Hirotaka Watanabe, Shuhei Nishina, Shugo Sasaki, Mitsuyoshi Takahara, Iichiro Shimomura, Tsunehiko Yamamoto
Publikováno v:
Journal of Diabetes Investigation, Vol 15, Iss 7, Pp 843-850 (2024)
ABSTRACT Aims/Introduction We aimed to evaluate factors that influence changes in blood low‐density lipoprotein cholesterol (LDL‐C) levels after treatment with sodium–glucose cotransporter 2 (SGLT2) inhibitors in Japanese patients with type 2 d
Externí odkaz:
https://doaj.org/article/51c146760f234b7c895706eaf6e39f6b
Autor:
Agena Suzuki, Akinori Hayashi, Satoshi Oda, Rei Fujishima, Naoya Shimizu, Kenta Matoba, Tomomi Taguchi, Takuya Toki, Takeshi Miyatsuka
Publikováno v:
Endocrine Journal, Vol 71, Iss 8, Pp 767-775 (2024)
The beneficial effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors in people with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD) have been suggested in several reports based on serological markers,
Externí odkaz:
https://doaj.org/article/00f5eb93060f4668a8fda6c2d44d6ba1
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundSodium-glucose cotransporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase-4 inhibitors (DPP4i) are important second-line treatments for patients with type 2 diabetes mellitus (T2DM). Patients taking SGLT2i have favorable cardiovascular ou
Externí odkaz:
https://doaj.org/article/d0dda332d00e499aa856bf64ce045f5e
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-12 (2024)
Abstract Background This study aimed to investigate the association of sodium-glucose cotransporter 2 inhibitors (SGLT2i) use with cardiovascular (CV) clinical outcomes in type 2 diabetes (T2D) patients with acute coronary syndrome (ACS). Methods Dat
Externí odkaz:
https://doaj.org/article/d42fc17a31084d758d50e8aa60b33b9e
Autor:
Ebaa Al-Ozairi, Kavita Narula, Alexander D. Miras, Etab Taghadom, Abeer El Samad, Jumana Al Kandari, Anas Alyosef, Anant Mashankar, Werd Al-Najim, Carel W. le Roux
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-14 (2024)
Abstract Background The guidelines of the American Diabetes Association and European Association for the Study of Diabetes suggest that patients with obesity type 2 diabetics and chronic kidney disease need either glucagon-like peptide 1 receptor ana
Externí odkaz:
https://doaj.org/article/9ec611ebeed94202ad96ba7c3113187e